Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen Designs: Nomograms and Tabulations01:23

Dosage Regimen Designs: Nomograms and Tabulations

Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bioprocess Development of a Human Monoclonal Antibody against MERS-CoV: Analytical and Preclinical Studies.

Biomolecules & therapeutics·2026
Same author

Enhancing triapine treatment: strategies for dose optimization and methemoglobin level mitigation.

Cancer chemotherapy and pharmacology·2026
Same author

Broad Neutralizing Activity of Monoclonal Antibodies Against the Omicron Variants Isolated From Patients With Early Severe Acute Respiratory Syndrome Coronavirus-2.

Journal of medical virology·2026
Same author

Unilateral Oculomotor Apraxia and Pseudodystonia in Joubert Syndrome Associated With Novel CPLANE1 Variant.

Movement disorders clinical practice·2026
Same author

Integrating polygenic and transcriptional risk scores for detecting Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

QStrain: an interactive platform for viral genome analysis and nucleic acid therapeutic design.

BMC bioinformatics·2026
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
Same journal

Methylglyoxal Promotes RBC-Driven Procoagulant Activity and Venous Thrombosis under Diabetes-Relevant Conditions.

Thrombosis and haemostasis·2026
Same journal

Management of Inferior Vena Cava Thrombosis: Guidance from the Italian Society for the Study of Haemostasis and Thrombosis.

Thrombosis and haemostasis·2026
See all related articles

Related Experiment Video

Updated: May 27, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

The Creating an Optimal Warfarin Nomogram (CROWN) Study.

Todd S Perlstein1, Samuel Z Goldhaber, Kerrie Nelson

  • 1Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.

Thrombosis and Haemostasis
|November 26, 2011
PubMed
Summary
This summary is machine-generated.

Optimizing warfarin dosing using pharmacogenetics and real-time data significantly improves patient outcomes. This adaptive approach enhances time within the therapeutic range for anticoagulation therapy.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Related Experiment Videos

Last Updated: May 27, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Area of Science:

  • Pharmacogenomics
  • Clinical Pharmacology
  • Internal Medicine

Background:

  • Warfarin dose variability is largely influenced by genetic variations in CYP2C9 and VKORC1 enzymes.
  • These enzymes are critical for warfarin metabolism and sensitivity, impacting therapeutic efficacy and safety.

Purpose of the Study:

  • To develop and refine an optimal warfarin dosing algorithm integrating both clinical and genetic factors.
  • To enhance the accuracy and effectiveness of warfarin pharmacogenetic dosing through iterative modeling.

Main Methods:

  • Enrolled patients initiating warfarin therapy and performed genotyping for VKORC1 and CYP2C9 variants.
  • Developed sequential dosing algorithms (A, B, C) using pharmacokinetic/pharmacodynamic modeling based on patient data.
  • Primary outcome measured was the time within the therapeutic international normalized ratio (INR) range (1.8-3.2).

Main Results:

  • The mean percentage of time within the therapeutic INR range increased progressively from Algorithm A (58.9%) to Algorithm C (65.8%) (p=0.04).
  • Significant improvements were observed in secondary endpoints, including reduced time outside the therapeutic range (p=0.004) and faster achievement of stable anticoagulation (p<0.001).

Conclusions:

  • Warfarin pharmacogenetic dosing can be adaptively optimized in real-time using observed pharmacokinetic/pharmacodynamic data.
  • This iterative, data-driven approach leads to improved anticoagulation control and patient outcomes.